梅花生物
(600873)
| 流通市值：268.37亿 | | | 总市值：268.37亿 |
| 流通股本：28.04亿 | | | 总股本：28.04亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,985,631,650.28 | 24,208,675,106.7 | 18,215,447,345 | 12,280,450,603.53 |
| 营业收入 | 5,985,631,650.28 | 24,208,675,106.7 | 18,215,447,345 | 12,280,450,603.53 |
| 二、营业总成本 | 5,882,482,412.56 | 21,603,821,463.14 | 15,834,727,996.42 | 10,368,912,543.02 |
| 营业成本 | 5,415,277,356.94 | 19,609,399,374.08 | 14,342,185,989.36 | 9,433,353,240.09 |
| 税金及附加 | 55,628,460.07 | 246,746,460.77 | 188,004,044.32 | 119,066,571.04 |
| 销售费用 | 81,998,236.22 | 362,971,160.8 | 273,352,514.87 | 167,760,792.02 |
| 管理费用 | 209,702,435.56 | 991,548,421.96 | 749,123,230.1 | 469,433,561.57 |
| 研发费用 | 94,329,806.93 | 389,151,493.26 | 296,016,607.21 | 199,958,697.93 |
| 财务费用 | 25,546,116.84 | 4,004,552.27 | -13,954,389.44 | -20,660,319.63 |
| 其中:利息费用 | 11,828,031.97 | 52,269,326.61 | 40,273,509.95 | 27,955,159.53 |
| 其中:利息收入 | 10,981,912.4 | 59,618,168.61 | 42,750,808.43 | 26,389,977.12 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,921,785.19 | 32,838,480.38 | 25,374,357.22 | 16,016,844.67 |
| 加:投资收益 | 11,986,698.51 | 57,847,648.05 | 42,049,338.03 | 29,250,766.79 |
| 资产处置收益 | 918,356.14 | 834,727.21 | 589,156.66 | 438,552.05 |
| 资产减值损失(新) | 66,100.94 | -36,034,934.84 | -9,348,180.66 | -9,236,606.64 |
| 信用减值损失(新) | 2,063,208.02 | 10,379,492.7 | 136,864.37 | -154,305.79 |
| 其他收益 | 17,168,441.37 | 238,343,273.35 | 219,409,461.61 | 148,546,316.33 |
| 四、营业利润 | 139,273,827.89 | 2,909,062,330.41 | 2,658,930,345.81 | 2,096,399,627.92 |
| 加:营业外收入 | 17,731,079.86 | 870,774,265.2 | 786,644,604.51 | 3,157,136.41 |
| 减:营业外支出 | 2,688,115.04 | 50,136,606.69 | 3,070,420.99 | 10,385,914.08 |
| 五、利润总额 | 154,316,792.71 | 3,729,699,988.92 | 3,442,504,529.33 | 2,089,170,850.25 |
| 减:所得税费用 | 36,395,828.64 | 448,820,076.82 | 417,412,174.28 | 321,220,733.36 |
| 六、净利润 | 117,920,964.07 | 3,280,879,912.1 | 3,025,092,355.05 | 1,767,950,116.89 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 117,920,964.07 | 3,280,879,912.1 | 3,025,092,355.05 | 1,767,950,116.89 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 117,920,964.07 | 3,280,879,912.1 | 3,025,092,355.05 | 1,767,950,116.89 |
| 扣除非经常损益后的净利润 | 80,256,263.63 | 2,205,459,805.05 | 2,019,475,140.77 | 1,628,363,104.4 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 1.17 | 1.06 | 0.62 |
| (二)稀释每股收益 | 0.04 | 1.17 | 1.06 | 0.62 |
| 八、其他综合收益 | -49,472,357.85 | -104,215,210.75 | -80,102,163.16 | -98,666,362.69 |
| 归属于母公司股东的其他综合收益 | -49,472,357.85 | -104,215,210.75 | -80,102,163.16 | -98,666,362.69 |
| 九、综合收益总额 | 68,448,606.22 | 3,176,664,701.35 | 2,944,990,191.89 | 1,669,283,754.2 |
| 归属于母公司股东的综合收益总额 | 68,448,606.22 | 3,176,664,701.35 | 2,944,990,191.89 | 1,669,283,754.2 |
| 公告日期 | 2026-04-22 | 2026-04-22 | 2025-10-30 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |